Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WAVE Life SciencesWVE -3.67%59 PB Ratio is 2.22 as of Jul. 15, 2026, which is 65% below its 10-year median of 6.43. GuruFocus rates WVE with a GF Score™ of 59/100 and a GF Value™ of $4.36 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,228 Biotechnology companies, WAVE Life Sciences ranks better than 59.12% on this metric.
WAVE Life Sciences Ltd stock PB Ratio (=2.31) is close to 10-year low of 2.15.
The historical rank and industry rank for WAVE Life Sciences's PB Ratio or its related term are showing as below:
WVE'
s PB Ratio Range Over the Past 10 Years
Min: 2.15 Med: 6.43 Max: 30.1
Current: 2.22
During the past 13 years, WAVE Life Sciences's highest PB Ratio was 30.10. The lowest was 2.15. And the median was 6.43.
WVE's PB Ratio is ranked better than 59.12% of 1228
companies
in the Biotechnology industry
Industry Median: 2.895
vs WVE: 2.22
During the past 12 months, WAVE Life Sciences's average Book Value Per Share Growth Rate was 138.70% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of WAVE Life Sciences was 36.10% per year. The lowest was -41.90% per year. And the median was -30.85% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
WAVE Life Sciences PB Ratio Related Terms
WAVE Life Sciences PB Ratio Historical Data
* Premium members only.
The historical data trend for WAVE Life Sciences's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, WAVE Life Sciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WAVE Life Sciences PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, WAVE Life Sciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where WAVE Life Sciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
WAVE Life Sciences (WVE) has a PB Ratio of 2.22 as of Jul. 15, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on WAVE Life Sciences and its competitors. This is 65% below median its historical median of 6.43. Over the past decade, WAVE Life Sciences' PB Ratio has ranged from 2.15 to 30.10. According to the industry distribution chart, WAVE Life Sciences ranks #502 out of 1228 companies in the Biotechnology industry, placing it in the top 40.9%.
Is WAVE Life Sciences' PB Ratio too high?
WAVE Life Sciences' current PB Ratio of 2.22 is 65% below median its 10-year median of 6.43. Over the past 10 years, this metric has ranged from a low of 2.15 to a high of 30.10. The Biotechnology industry median PB Ratio is 2.90. WAVE Life Sciences' value of 2.22 is 23.3% below this industry median. Based on the distribution chart, WAVE Life Sciences ranks #502 out of 1228 companies in the Biotechnology industry, which is above the industry midpoint. Overall, WAVE Life Sciences has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does WAVE Life Sciences' PB Ratio compare to CGEM and LXRX?
According to the Biotechnology industry distribution chart, WAVE Life Sciences ranks #502 out of 1228 companies for PB Ratio. This puts WAVE Life Sciences in the upper half of its industry. The industry median PB Ratio is 2.90. WAVE Life Sciences' value of 2.22 is 23.3% below this benchmark. Historically, WAVE Life Sciences' own PB Ratio has ranged from 2.15 to 30.10 over the past decade. While the company's 10-year median is 6.43 vs. the industry median of 2.90, WAVE Life Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.90, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WAVE Life Sciences's current PB Ratio of 2.22 is 23.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on WAVE Life Sciences and its competitors. For the Biotechnology industry, the median PB Ratio is 2.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WAVE Life Sciences's current PB Ratio is 2.22, which is 65% below median its own 10-year median of 6.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WAVE Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, WAVE Life Sciences (WVE) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.36, compared to a current price of $5.91 — trading 35.6% above its estimated fair value. The current PB Ratio is 2.22, which is 65% below median its 10-year median of 6.43 and 23.3% below the Biotechnology industry median of 2.90. WAVE Life Sciences' overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For WAVE Life Sciences (WVE), the current PB Ratio is 2.22 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WAVE Life Sciences (WVE) Overvalued in 2026?
Based on GuruFocus' analysis, WAVE Life Sciences stock appears to be overvalued.
The current stock price of $5.91 is trading 35.6% above its estimated GF Value™ of $4.36.
GuruFocus considers WAVE Life Sciences to be Significantly Overvalued.
Key valuation signals for WVE:
PB Ratio: 2.22 (65% below median its 10-year median of 6.43)
GF Value™: $4.36 vs. price of $5.91 (35.6% above fair value)
Industry Position: 23.3% below the Biotechnology median (#502 of 1228)
No single metric tells the full story. See the WVE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
59GF Score
Get the complete analysis for WVE
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WVE has been successfully added to your 
